Methods: The Telavancin Observational Use Registry (TOUR™) is a multicenter chart review study designed to characterize infection types, pathogens, and outcomes of patients treated with TLV in clinical practice. Data from TOUR were used to characterize a subset of patients with bacteremia and IE. Clinical data including patient demographics, pathogens, outcomes, and adverse events (AEs) were analyzed. Clinical outcomes were determined by investigators’ assessment.
Results: As of March 31, 2017, data for more than 1000 patients were collected from 46 sites. Of these, 148 patients were treated for bacteremia and/or IE. Among these 148 patients, median age was 59 years (range 18−88 years) and 34% (n = 51) were aged ≥65 years, 55% (n = 81) were male, and 79% (n = 117) were White. The median body mass index was 27.3 kg/m2 (range 13.5−57.9 kg/m2). MRSA was the most commonly isolated pathogen at baseline (57%; n = 84). The median TLV daily dose and duration of treatment were 750 mg (range 250−1500 mg) or 8.9 mg/kg (range 2.9−15.0 mg/kg) and 9 days (range 1−70 days), respectively. Telavancin was used as second-line therapy in 85% (n = 126) of patients, and the majority of patients (78%; n = 115) were treated as inpatients. Overall, 66% (n = 97) of patients were cured or improved to step-down therapy, 9% (n = 13) failed treatment, 14% (n = 21) had an indeterminate clinical outcome at end of therapy (EOT), and 11% (n = 17) had missing or undocumented outcomes. Among the patients who had outcome assessment at EOT (n = 131), 74% were cured or improved to step-down therapy and 10% failed therapy. AEs were reported in 25 patients; 18 reported a serious AE, and 16 had AEs leading to TLV discontinuation.
Conclusion: In a real-world setting, once-daily TLV produced positive clinical responses in patients with SAB and/or IE, and may represent an alternative treatment option in these serious infections.
Theravance Biopharma US, Inc.:
A. Lat, Theravance Biopharma US, Inc.: Employee and Shareholder , Salary
A. Osmukhina, Theravance Biopharma US, Inc.: Employee and Shareholder , RSU, Stock Options and Salary
B. Castaneda-Ruiz, Theravance Biopharma US, Inc.: Employee and Shareholder , Salary
See more of: Poster Abstract Session